- Home
- SONN vs DRMA Comparison
SONN vs DRMA Comparison
Compare SONN & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SONN
- DRMA
- Stock Information
- Founded
- SONN N/A
- DRMA 2014
- Country
- SONN United States
- DRMA United States
- Employees
- SONN N/A
- DRMA N/A
- Industry
- SONN Biotechnology: Pharmaceutical Preparations
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- SONN Health Care
- DRMA Health Care
- Exchange
- SONN Nasdaq
- DRMA Nasdaq
- Market Cap
- SONN 2.5M
- DRMA 2.2M
- IPO Year
- SONN N/A
- DRMA 2021
- Fundamental
- Price
- SONN $1.51
- DRMA $1.33
- Analyst Decision
- SONN Strong Buy
- DRMA Strong Buy
- Analyst Count
- SONN 2
- DRMA 1
- Target Price
- SONN $38.00
- DRMA $6.00
- AVG Volume (30 Days)
- SONN 2.8M
- DRMA 691.8K
- Earning Date
- SONN 12-17-2024
- DRMA 11-13-2024
- Dividend Yield
- SONN N/A
- DRMA N/A
- EPS Growth
- SONN N/A
- DRMA N/A
- EPS
- SONN N/A
- DRMA N/A
- Revenue
- SONN $18,626.00
- DRMA N/A
- Revenue This Year
- SONN N/A
- DRMA N/A
- Revenue Next Year
- SONN N/A
- DRMA N/A
- P/E Ratio
- SONN N/A
- DRMA N/A
- Revenue Growth
- SONN N/A
- DRMA N/A
- 52 Week Low
- SONN $1.41
- DRMA $1.00
- 52 Week High
- SONN $18.72
- DRMA $13.35
- Technical
- Relative Strength Index (RSI)
- SONN 26.27
- DRMA 56.82
- Support Level
- SONN $1.41
- DRMA $1.00
- Resistance Level
- SONN $1.94
- DRMA $1.41
- Average True Range (ATR)
- SONN 0.37
- DRMA 0.13
- MACD
- SONN 0.05
- DRMA 0.03
- Stochastic Oscillator
- SONN 2.91
- DRMA 73.33
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.